Amarin Corp Plc

The U.S. Supreme Court unanimously ruled in favor of Hikma Pharmaceuticals in a patent infringement case brought by Amarin. The dispute centered on Hikma's generic icosapent ethyl (a fish oil-based medicine for severe hypertriglyceridemia), which Hikma launched in 2020 with a 'skinny label' covering only non-patented uses. The ruling allows Hikma...

Amarin faces significant challenges as its sole drug, Vascepa, encounters generic competition in the U.S. market, causing revenue to decline from $285 million two years ago to $183 million in 2025. While the company maintains a strong balance sheet with no debt and is restructuring to achieve positive free cash flow, its single-product dependency...

Recordati reported strong financial performance in Q3 2025, with revenue up 12.2% to €1,956.2 million, driven by growth in Rare Diseases and Specialty & Primary Care segments. The company doubled its peak sales estimate for Isturisa to over €1.2 billion and expects Rare Diseases to approach 50% of total revenues in 2026.

Amarin presented a new post hoc analysis of the REDUCE-IT study demonstrating that icosapent ethyl (VASCEPA/VAZKEPA) significantly reduced cardiovascular events in high-risk patients, with consistent benefits observed in both aspirin users and non-users.

Amarin and HLS Therapeutics will present scientific data at the Canadian Cardiovascular Congress, highlighting the clinical value of Icosapent Ethyl (IPE) for cardiometabolic conditions and exploring EPA's mechanistic effects on cardiovascular health.